PerpEquities

Equity · Healthcare

Merck & Co., Inc. (MRK) perpetual futures

MRK perpetual futures on 14 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade MRKUSDT.

Merck & Co., Inc. is a global healthcare leader operating in Pharmaceuticals and Animal Health, offering medicines, vaccines, and animal health solutions to customers including wholesalers, pharmacies, hospitals, and government agencies.

$144.69+0.5%NYSE open
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NYSE:MRK

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

14/14 live markets
Venues
14
Live markets
14/14
24h volume
$2.1MCoverage: 13/14 marketsExchange-reported volume: $3.4M
Open interest
$4.2MCoverage: 12/14 markets
Best liquidity
$5M
LBank
Tightest spread
+0.7 bps
BingX
Highest volume
$1.2M
BingX
Settlement mix
USDT · 14/14
Perp/spot vol.
0.00x
Spot volume $1.6B
OI / float
0.00%
Float $356.6B
Spot performance
1D+0.53%
5D+2.00%
1M-0.62%
6M+22.59%
YTD+38.67%
1Y+69.10%

Venue matrix

14 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
OurbitTradeMRK/USDTTrading$144.710.0% APR
0.000% every 8h
+2.8 bps$116.4K$329K$115.2KUSDT20x
HTXTradeMRK/USDTTrading$144.64-+1,780.0 bps$0$161.1K-USDT-
BinanceTradeMRK/USDTTrading$144.710.0% APR
0.000% every 8h
+2.8 bps-$131.4K$88.8KUSDT-
MEXCTradeMRK/USDTTrading$144.700.0% APR
0.000% every 8h
+22.1 bps$349.7K$114.8K$370.3KUSDT20x
BitunixTradeMRK/USDTTrading$144.59+1.2% APR
+0.00105% every 8h
+0.7 bps$34K$72.7K$37.1KUSDT20x
XT.comTradeMRK/USDTTrading$144.680.0% APR
0.000% every 8h
+51.1 bps$50.4K$25.7K$2.4MUSDT20x
OKXTradeMRK/USDTTrading$144.550.0% APR
0.000% every 8h
+14.5 bps$14.8K$23.9K$126.4KUSDT10x
PhemexTradeMRK / USDTTrading$144.730.0% APR
0.000% every 8h
+13.1 bps$48.8K$14K$284.8KUSDT20x
BloFinTradeMRK/USDTTrading$144.72-3.1% APR
-0.00281% every 8h
+11.1 bps$1.1M$13.5K$31.7KUSDT20x
BitgetTradeMRK/USDTTrading$144.640.0% APR
0.000% every 8h
+4.1 bps$463.2K$13K$432.3KUSDT20x
BybitTradeMRK/USDTTrading$144.640.0% APR
0.000% every 8h
+38.7 bps$28.3K$9.4K$166.5KUSDT25x
Gate.ioTradeMRK/USDTTrading$144.600.0% APR
0.000% every 8h
+2.1 bps-$709$118KUSDT20x
BingXTradeMRK-USDTTrading$144.67+5.5% APR
+0.00500% every 8h
+0.7 bps$534.8K$1.2M-USDT-
LBankTradeMRK/USDTTrading$144.690.0% APR
0.000% every 8h
+2.8 bps$5M$1.2M⚠$9.4KUSDT50x

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Broad liquidity · 12 of 14 venues absorb $10k · Typical cost: +14.6 bps – +39.8 bps

Cheapest execution: LBank · +7.8 bps

No fresh book data: HTX, Gate.io

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

MRK

Tightest spread

MRK

Highest volume

MRK

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 2h ago
Market cap
$358.3B
Updated 2h ago
Revenue
$66.4B
Trailing 12 months
Revenue growth
+3%
Next fiscal year
Profit margin
+4.8%
P/E
115.2
Peer P/E 24.7
Free cash flow
$16.1B
Trailing 12 months
More metrics
Net income
$3.2B
Trailing 12 months
P/S
5.4
Peer P/E
24.7
Similar listed perps
Revenue estimate
$67B
Next fiscal year
Earnings
2026-10-29
Revenue est. $17.3B · Updated 2h ago
Dividend
$0.85
2026-09-15

Fundamental detail

Annual + quarterly
Latest revenue$64.9B
Net margin+28.1%
Free cash flow$12.4B
Net debt$36B
2020$41.5B
2021$48.7B
2022$59.3B
2023$60.1B
2024$64.2B
2025$64.9B
PeriodRevenueGrowthNet incomeFCF
2020$41.5B+6%$7.1B$5.8B
2021$48.7B+17%$13B$9.7B
2022$59.3B+22%$14.5B$14.7B
2023$60.1B+1%$365M$9.1B
2024$64.2B+7%$17.1B$18.1B
2025$64.9B+1%$18.3B$12.4B
PeriodGross marginOperating marginNet marginROEROA
2020+67.2%+13.4%+17.0%+27.9%+7.7%
2021+72.0%+27.1%+26.8%+34.2%+12.3%
2022+70.6%+30.8%+24.5%+31.6%+13.3%
2023+73.2%+4.9%+0.6%+1.0%+0.3%
2024+76.3%+31.5%+26.7%+37.0%+14.6%
2025+72.0%+36.2%+28.1%+34.7%+13.3%
PeriodCashDebtNet debtCurrent ratio
2020$8.1B$33.4B$25.4B1.02
2021$8.1B$34.6B$26.5B1.27
2022$12.7B$32B$19.3B1.47
2023$6.8B$36.3B$29.4B1.25
2024$13.2B$38.3B$25B1.36
2025$14.6B$50.5B$36B1.54
PeriodMarket capEnterprise valueP/SP/E
2020$197.3B$222.7B4.828.0
2021$193.9B$220.4B4.014.9
2022$280.9B$300.2B4.719.4
2023$277.7B$307.1B4.6778.7
2024$251.9B$276.9B3.914.7
2025$263.4B$299.3B4.114.4
Q3 2024$16.7B
Q4 2024$15.6B
Q1 2025$15.6B
Q2 2025$15.8B
Q3 2025$17.2B
Q4 2025$16.3B
Q1 2026$16.3B
Q2 2026$16.6B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$16.7B+4%$3.2B$8.5B
Q4 2024$15.6B+7%$3.7B$2.5B
Q1 2025$15.6B-1%$5.1B$1.2B
Q2 2025$15.8B-2%$4.4B$2.5B
Q3 2025$17.2B+3%$5.8B$6.8B
Q4 2025$16.3B+4%$3B$1.8B
Q1 2026$16.3B+4%-$4.2B$2.9B
Q2 2026$16.6B+5%-$1.3B$4.5B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+75.5%+23.9%+19.0%+7.1%+2.7%
Q4 2024+75.5%+27.8%+24.0%+8.1%+3.2%
Q1 2025+75.1%+43.0%+32.5%+10.5%+4.4%
Q2 2025+75.7%+40.2%+28.0%+9.0%+3.8%
Q3 2025+75.6%+43.4%+33.7%+11.2%+4.5%
Q4 2025+70.5%+37.7%+18.2%+5.6%+2.2%
Q1 2026+81.9%-11.6%-26.0%-9.2%-3.3%
Q2 2026+73.5%-4.1%-8.0%-3.2%-1.0%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$14.6B$38.1B$23.5B1.36
Q4 2024$13.2B$38.3B$25B1.36
Q1 2025$8.6B$34.8B$26.2B1.41
Q2 2025$8B$35.4B$27.4B1.42
Q3 2025$18.2B$41.4B$23.2B1.66
Q4 2025$14.6B$50.5B$36B1.54
Q1 2026$5.3B$49.1B$43.8B1.30
Q2 2026$6.8B$53.9B$47.1B1.32
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$288.6B$312.1B17.322.7
Q4 2024$252.8B$277.8B16.216.8
Q1 2025$226.5B$252.7B14.511.2
Q2 2025$198.7B$226.1B12.611.2
Q3 2025$209.4B$232.6B12.29.0
Q4 2025$260.5B$296.4B16.021.9
Q1 2026$297.4B$341.1B18.3-17.5
Q2 2026$317.7B$364.7B19.1-59.5

Refreshed 2h ago

Charts: revenue, profit, cash flow & valuation
Revenue$16.6BQ2 2026
$4.3B$8.6B$12.9B$17.2BQ3 2023: $16BQ4 2023: $14.6BQ1 2024: $15.8BQ2 2024: $16.1BQ3 2024: $16.7BQ4 2024: $15.6BQ1 2025: $15.6BQ2 2025: $15.8BQ3 2025: $17.2BQ4 2025: $16.3BQ1 2026: $16.3BQ2 2026: $16.6BQ3 2023Q2 2026
Net income-$1.3BQ2 2026
-$1.7B$772.5M$3.3B$5.8BQ3 2023: $4.7BQ4 2023: -$1.2BQ1 2024: $4.8BQ2 2024: $5.5BQ3 2024: $3.2BQ4 2024: $3.7BQ1 2025: $5.1BQ2 2025: $4.4BQ3 2025: $5.8BQ4 2025: $3BQ1 2026: -$4.2BQ2 2026: -$1.3BQ3 2023Q2 2026
EBITDA$1.4BQ2 2026
$540M$3.1B$5.7B$8.2BQ3 2023: $7BQ4 2023: -$772MQ1 2024: $7BQ2 2024: $7.4BQ3 2024: $5.6BQ4 2024: $5.7BQ1 2025: $7.3BQ2 2025: $6.4BQ3 2025: $8.2BQ4 2025: $6.3BQ1 2026: -$2BQ2 2026: $1.4BQ3 2023Q2 2026
Free cash flow$4.5BQ2 2026
$1.6B$3.9B$6.2B$8.5BQ3 2023: $6.8BQ4 2023: -$743MQ1 2024: $2.2BQ2 2024: $4.8BQ3 2024: $8.5BQ4 2024: $2.5BQ1 2025: $1.2BQ2 2025: $2.5BQ3 2025: $6.8BQ4 2025: $1.8BQ1 2026: $2.9BQ2 2026: $4.5BQ3 2023Q2 2026
EPS-$0.54Q2 2026
-$0.71$0.3$1.31$2.32Q3 2023: $1.86Q4 2023: -$0.48Q1 2024: $1.87Q2 2024: $2.14Q3 2024: $1.24Q4 2024: $1.48Q1 2025: $2.01Q2 2025: $1.76Q3 2025: $2.32Q4 2025: $1.19Q1 2026: -$1.72Q2 2026: -$0.54Q3 2023Q2 2026
Cash / Debt$6.8BQ2 2026
$13.5B$27B$40.4B$53.9BQ3 2023 · Cash: $8.6BQ3 2023 · Debt: $34.9BQ4 2023 · Cash: $6.8BQ4 2023 · Debt: $36.3BQ1 2024 · Cash: $5.6BQ1 2024 · Debt: $34.2BQ2 2024 · Cash: $11.3BQ2 2024 · Debt: $37.8BQ3 2024 · Cash: $14.6BQ3 2024 · Debt: $38.1BQ4 2024 · Cash: $13.2BQ4 2024 · Debt: $38.3BQ1 2025 · Cash: $8.6BQ1 2025 · Debt: $34.8BQ2 2025 · Cash: $8BQ2 2025 · Debt: $35.4BQ3 2025 · Cash: $18.2BQ3 2025 · Debt: $41.4BQ4 2025 · Cash: $14.6BQ4 2025 · Debt: $50.5BQ1 2026 · Cash: $5.3BQ1 2026 · Debt: $49.1BQ2 2026 · Cash: $6.8BQ2 2026 · Debt: $53.9BQ3 2023Q2 2026
CashDebt
Profitability+73.5%Q2 2026
+1.0%+27.9%+54.9%+81.9%Q3 2023 · Gross margin: +73.3%Q4 2023 · Gross margin: +73.3%Q1 2024 · Gross margin: +77.6%Q2 2024 · Gross margin: +76.8%Q3 2024 · Gross margin: +75.5%Q4 2024 · Gross margin: +75.5%Q1 2025 · Gross margin: +75.1%Q2 2025 · Gross margin: +75.7%Q3 2025 · Gross margin: +75.6%Q4 2025 · Gross margin: +70.5%Q1 2026 · Gross margin: +81.9%Q2 2026 · Gross margin: +73.5%Q3 2023 · Operating margin: +36.8%Q4 2023 · Operating margin: -11.7%Q1 2024 · Operating margin: +36.5%Q2 2024 · Operating margin: +38.0%Q3 2024 · Operating margin: +23.9%Q4 2024 · Operating margin: +27.8%Q1 2025 · Operating margin: +43.0%Q2 2025 · Operating margin: +40.2%Q3 2025 · Operating margin: +43.4%Q4 2025 · Operating margin: +37.7%Q1 2026 · Operating margin: -11.6%Q2 2026 · Operating margin: -4.1%Q3 2023 · Net margin: +29.7%Q4 2023 · Net margin: -8.4%Q1 2024 · Net margin: +30.2%Q2 2024 · Net margin: +33.9%Q3 2024 · Net margin: +19.0%Q4 2024 · Net margin: +24.0%Q1 2025 · Net margin: +32.5%Q2 2025 · Net margin: +28.0%Q3 2025 · Net margin: +33.7%Q4 2025 · Net margin: +18.2%Q1 2026 · Net margin: -26.0%Q2 2026 · Net margin: -8.0%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+5.1%Q2 2026
+0.3%+2.6%+4.9%+7.2%Q2 2024: +7.2%Q3 2024: +4.4%Q4 2024: +6.8%Q1 2025: -1.0%Q2 2025: -1.9%Q3 2025: +3.2%Q4 2025: +4.5%Q1 2026: +4.3%Q2 2026: +5.1%Q3 2023Q2 2026
Shares outstanding2.5BQ2 2026
638.5M1.3B1.9B2.6BQ3 2023: 2.5BQ4 2023: 2.6BQ1 2024: 2.5BQ2 2024: 2.5BQ3 2024: 2.5BQ4 2024: 2.5BQ1 2025: 2.5BQ2 2025: 2.5BQ3 2025: 2.5BQ4 2025: 2.5BQ1 2026: 2.5BQ2 2026: 2.5BQ3 2023Q2 2026
Valuation-59.5Q2 2026
-38.9-18.42.222.7Q3 2023 · P/E: 13.8Q4 2023 · P/E: -56.8Q1 2024 · P/E: 17.4Q2 2024 · P/E: 14.9Q3 2024 · P/E: 22.7Q4 2024 · P/E: 16.8Q1 2025 · P/E: 11.2Q2 2025 · P/E: 11.2Q3 2025 · P/E: 9.0Q4 2025 · P/E: 21.9Q1 2026 · P/E: -17.5Q2 2026 · P/E: -59.5Q3 2023 · P/S: 16.4Q4 2023 · P/S: 19.0Q1 2024 · P/S: 21.0Q2 2024 · P/S: 20.1Q3 2024 · P/S: 17.3Q4 2024 · P/S: 16.2Q1 2025 · P/S: 14.5Q2 2025 · P/S: 12.6Q3 2025 · P/S: 12.2Q4 2025 · P/S: 16.0Q1 2026 · P/S: 18.3Q2 2026 · P/S: 19.1Q3 2023Q2 2026
P/EP/S
Revenue$64.9B2025
$16.2B$32.5B$48.7B$64.9B2018: $42.3B2019: $39.1B2020: $41.5B2021: $48.7B2022: $59.3B2023: $60.1B2024: $64.2B2025: $64.9B20182025
Net income$18.3B2025
$4.6B$9.1B$13.7B$18.3B2018: $6.2B2019: $9.8B2020: $7.1B2021: $13B2022: $14.5B2023: $365M2024: $17.1B2025: $18.3B20182025
EBITDA$28.3B2025
$7.1B$14.1B$21.2B$28.3B2018: $14B2019: $16B2020: $10.2B2021: $17.9B2022: $21.3B2023: $6.9B2024: $25.7B2025: $28.3B20182025
Free cash flow$12.4B2025
$4.5B$9B$13.6B$18.1B2018: $8.3B2019: $10B2020: $5.8B2021: $9.7B2022: $14.7B2023: $9.1B2024: $18.1B2025: $12.4B20182025
EPS$7.282025
$1.82$3.64$5.46$7.282018: $2.322019: $3.822020: $2.782021: $5.142022: $5.712023: $0.142024: $6.742025: $7.2820182025
Cash / Debt$14.6B2025
$12.6B$25.3B$37.9B$50.5B2018 · Cash: $8B2018 · Debt: $25.1B2019 · Cash: $9.7B2019 · Debt: $27.4B2020 · Cash: $8.1B2020 · Debt: $33.4B2021 · Cash: $8.1B2021 · Debt: $34.6B2022 · Cash: $12.7B2022 · Debt: $32B2023 · Cash: $6.8B2023 · Debt: $36.3B2024 · Cash: $13.2B2024 · Debt: $38.3B2025 · Cash: $14.6B2025 · Debt: $50.5B20182025
CashDebt
Profitability+72.0%2025
+19.1%+38.2%+57.2%+76.3%2018 · Gross margin: +68.1%2019 · Gross margin: +69.3%2020 · Gross margin: +67.2%2021 · Gross margin: +72.0%2022 · Gross margin: +70.6%2023 · Gross margin: +73.2%2024 · Gross margin: +76.3%2025 · Gross margin: +72.0%2018 · Operating margin: +21.1%2019 · Operating margin: +20.3%2020 · Operating margin: +13.4%2021 · Operating margin: +27.1%2022 · Operating margin: +30.8%2023 · Operating margin: +4.9%2024 · Operating margin: +31.5%2025 · Operating margin: +36.2%2018 · Net margin: +14.7%2019 · Net margin: +25.2%2020 · Net margin: +17.0%2021 · Net margin: +26.8%2022 · Net margin: +24.5%2023 · Net margin: +0.6%2024 · Net margin: +26.7%2025 · Net margin: +28.1%20182025
Gross marginOperating marginNet margin
Revenue growth+1.2%2025
-0.2%+7.1%+14.4%+21.7%2019: -7.5%2020: +6.1%2021: +17.3%2022: +21.7%2023: +1.4%2024: +6.7%2025: +1.2%20182025
Shares outstanding2.5B2025
669.8M1.3B2B2.7B2018: 2.7B2019: 2.6B2020: 2.5B2021: 2.5B2022: 2.5B2023: 2.5B2024: 2.5B2025: 2.5B20182025
Valuation14.42025
194.7389.4584.0778.72018 · P/E: 30.42019 · P/E: 22.62020 · P/E: 28.02021 · P/E: 14.92022 · P/E: 19.42023 · P/E: 778.72024 · P/E: 14.72025 · P/E: 14.42018 · P/S: 4.52019 · P/S: 5.72020 · P/S: 4.82021 · P/S: 4.02022 · P/S: 4.72023 · P/S: 4.62024 · P/S: 3.92025 · P/S: 4.120182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-10-29
Revenue est. $17.3B · Updated 2h ago
Dividend
$0.85
2026-09-15

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20262.65$67B+3%13
FY 20279.25$69.8B+7%12
FY 202810.22$73.8B+14%7
FY 20299.98$74.5B+15%2
FY 20309.90$75.1B+16%4
Q1 20272.14$16.5B+1%8

Company events

6
2026-10-29Earnings · Before market openActual - / Estimate 2.09-
2026-09-15Dividend$0.85-
2026-08-04EarningsActual -0.13 / Estimate -0.27Beat
2026-06-15Dividend$0.85-
2026-04-30EarningsActual -1.28 / Estimate -1.47Beat
2026-03-16Dividend$0.85-

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Oct 19, 2026, 04:43 PM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Robert Davis
Employees
74,000
IPO date
Jan 13, 1978
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei3.92
Piotroski scorei5/9
FMP ratingiB-
Owner earningsi$4.79B$1.94 per share
ESG risk ratingiB+Industry rank: 2 out of 28

Rating factors

Return on equityi
3
Return on assetsi
4
Debt to equityi
1
Price to earningsi
1
Price to booki
1
Market cap history
$360.79B+17.3%Jul 26 – Oct 26
$307.52B$339.98B$372.43BHigh: $372.43B · 2026-08-24Low: $307.52B · 2026-07-20Latest: $360.79B · 2026-10-16Jul 26Aug 26Sep 26Oct 26
Latest: $360.79B · 2026-10-16High: $372.43B · 2026-08-24Low: $307.52B · 2026-07-20
Largest fund holders
FundWeightShares held
VTI0.49%78.5M
VOO0.55%65.6M
IVV0.52%32.8M
XAW.TO0.32%32.8M
XWD.TO0.39%32.8M
XUS.TO0.53%32.8M
1657.T0.41%32.8M
FXAIX0.55%32.7M
SCHD4.01%30.6M
SPY0.53%30.2M
VTV1.33%23.6M
VGHAX6.05%18.3M

Analyst track record

How the analysts covering MRK have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings229583
Analysts2743
Buy / hold / sell157 / 72 / 0403 / 178 / 2
Upgrades / downgrades / initiations6 / 1 / 39 / 10 / 10
Price targets hit / missed157 / 61 (72%)439 / 83 (84%)
Avg. return after a rating (TipRanks)+10.2%+16.9%
Best / worst call+77.1% / -19.3%+77.1% / -19.3%

After buy calls on this stock: median 21-day move 0.0% vs S&P 500 -1.2% (n = 396)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Asad HaiderGoldman Sachs100% hit rate on this stock · 8 targets measuredBuytarget $160Sep 30, 2026
  2. Tim AndersonBank of America Securities82% hit rate on this stock · 11 targets measuredBuytarget $105Nov 17, 2025
  3. Daina GrayboschLeerink Partners75% hit rate on this stock · 24 targets measuredBuytarget $161Oct 12, 2026

Latest ratings

DateAnalystCallTarget
Oct 16, 2026Trung HuynhRBC CapitalHoldMaintained$145
Oct 16, 2026Trung HuynhRBC CapitalHoldMaintained$145
Oct 16, 2026Geoff MeachamCitiHoldMaintained$145
Oct 15, 2026Mohit BansalWells FargoBuyMaintained$165
Oct 15, 2026Mohit BansalWells FargoBuyMaintained$165
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$110$120$130$140$150$160Nov 25 · Buy 10 · Hold 9 · Sell 0Nov 25Dec 25 · Buy 12 · Hold 8 · Sell 0Jan 26 · Buy 14 · Hold 8 · Sell 0Jan 26Feb 26 · Buy 17 · Hold 7 · Sell 0Mar 26 · Buy 17 · Hold 6 · Sell 0Mar 26Apr 26 · Buy 18 · Hold 7 · Sell 0May 26 · Buy 19 · Hold 7 · Sell 0May 26Jun 26 · Buy 16 · Hold 7 · Sell 0Jul 26 · Buy 15 · Hold 7 · Sell 0Jul 26Aug 26 · Buy 15 · Hold 7 · Sell 0Sep 26 · Buy 16 · Hold 7 · Sell 0Sep 26Oct 26 · Buy 16 · Hold 7 · Sell 0Nov 25 · avg. target $105Dec 25 · avg. target $110Jan 26 · avg. target $117Feb 26 · avg. target $125Mar 26 · avg. target $129Apr 26 · avg. target $133May 26 · avg. target $134Jun 26 · avg. target $138Jul 26 · avg. target $139Aug 26 · avg. target $152Sep 26 · avg. target $161Oct 26 · avg. target $159Nov 25 · month-end close $105Dec 25 · month-end close $105Jan 26 · month-end close $110Feb 26 · month-end close $124Mar 26 · month-end close $120Apr 26 · month-end close $109May 26 · month-end close $119Jun 26 · month-end close $129Jul 26 · month-end close $130Aug 26 · month-end close $148Sep 26 · month-end close $145Oct 26 · month-end close $146

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Oct 17, 2026 · 229 ratings

Frequently asked questions

Where can I trade MRK perpetual futures?

Merck & Co., Inc. (MRK) perpetual futures trade on 14 crypto venues, including LBank, BingX, Ourbit. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade MRK around the clock?

Yes. Unlike the underlying stock, MRK perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on MRK perpetuals?

Right now the MRK perp funding rate is 0.0% annualized (venue median), ranging from -3.1% to +5.5% across 14 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the MRK perp price compare to the Merck & Co., Inc. stock?

The venue-median MRK perp mark is $144.7 versus a reference stock price of $144.7, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a MRK perpetual future?

A MRK perpetual is a derivative that tracks the price of Merck & Co., Inc. with no expiry date. It lets you take long or short exposure to Merck & Co., Inc. on crypto venues, around the clock.

What is MRKUSDT perpetual?

MRKUSDT is the symbol most crypto exchanges use for the Merck & Co., Inc. perpetual settled in USDT (Tether). It tracks the MRK share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

MRK perpetuals · perpequities.comMRK perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/mrk-perp"><img src="https://perpequities.com/badge/mrk-perp.svg" width="240" height="64" alt="MRK perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of MRK perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for MRK — one email every Sunday.

Watchlist and alerts

Price and funding alerts for MRK, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X